Ziconotide infusion for severe chronic pain: Case series of patients with neuropathic pain

Pharmacotherapy

Volumn 26, Issue 3, 2006, Pages 395-402

  Wermeling, Daniel P ^a,b   Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Kentucky   (United States)

Author keywords

Case series; Chronic pain; Complex regional pain syndrome; Epidural delivery; Intrathecal delivery; Neuropathic pain; Ziconotide

Indexed keywords

ALPRAZOLAM; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BACLOFEN; BUPIVACAINE; CARBAMAZEPINE; CLONAZEPAM; COTRIMOXAZOLE; CYCLOBENZAPRINE; DIPHENHYDRAMINE; FLUOXETINE; GABAPENTIN; HYDROCODONE BITARTRATE PLUS PARACETAMOL; MORPHINE DERIVATIVE; NAPROXEN; OMEGA CONOTOXIN MVIIA; OXYCODONE; PETHIDINE; PROCHLORPERAZINE; PROPRANOLOL; QUAZEPAM; ROFECOXIB; ZOLPIDEM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANALGESIA; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; CONFUSION; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; MALE; MEMORY DISORDER; MENINGITIS; NAUSEA; NEUROPATHIC PAIN; PHYSIOTHERAPY; PRURITUS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TOXICITY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANALGESICS, NON-NARCOTIC; FEMALE; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; NEURALGIA; OMEGA-CONOTOXINS;

EID: 33644672265     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.3.395     Document Type: Article

References (20)

1. Elan Pharmaceuticals, Inc. Prialt (ziconotide intrathecal infusion) product information. San Diego, CA; 2005. Available from www.prialt.com. Accessed June 6, 2005.
2. Hillyard DR, Monje VD, Mintz IM, et al. A new Conus peptide ligand for mammalian presynaptic calcium channels. Neuron 1992;9:69-77.
3. Sato K, Raymond C, Martin-Moutot N, et al. Binding of chimeric analogs of ω-conotoxin MVIIA and MVIIC to the N-and P/Q type calcium channels. FEBS Lett 1997;414:480-4.
4. Lewis RJ, Nielsen KJ, Criak DJ, et al. Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000;275:35335-44.
5. Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of ω-conopeptides, N-type calcium channel blockers, on behavior and antinociception in the formalin and hot plate tests in rats. Pain 1995;60:83-90.
6. Wank Y, Gao D, Pettus M, Phillips C, Bowersox SS. Interaction of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage sensitive calcium channels with morphine on nociception in rats. Pain 2000;84:271-81.
7. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005;25:1084-94.
8. Atanassoff PG, Harmansgrubber MWB, Thrasher J, et al. Ziconotide, a new calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000;25:274-8.
9. Wermeling DP, Drass M, Ellis D, et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 2003;43:624-36.
10. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA 2004;291:63-70.
11. Brose WG. Use of intrathecal SNX-111, a novel N-type voltage sensitive calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997;13:256-9.
12. Staats PS, Luthardt MA, Shipley J, et al. Long-term intrathecal ziconotide therapy: a case study and discussion. Neuromodulation 2001;4:121-6.
13. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000;85: 291-6.
14. Levin T, Petrides G, Weiner J, et al. Intractable delirium associated with ziconotide successfully treated with electroconvulsive therapy. Psychosomatics 2002;43:63-6.
15. Webster L, Henderson R, Katz N, Ellis D. Characterization of confusion, an adverse event associated with intrathecal ziconotide in chronic pain patients. Pain Med 2001;21:253-4.
16. Ridgeway B, Wallace M, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000;85:287-9.
17. Marshall D, Belder MD. Epidural opioid therapy for chronic nonmalignant pain: critique of current experience. J Pain Symptom Manage 1996;11:353-6.
18. Dickson D. Risks and benefits of long-term intrathecal analgesia. Anaesthesia 2004;59:631-5.
19. McGuire D, Bowersox S, Fellmann JD, Luther RR. Sympatholysis after neuron specific, N-type, voltage sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol 1997;30:400-3.
20. Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic consensus conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage 2004;27:540-63.